Clinical Trial: A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment

Brief Summary: This study is being conducted to help determine whether β-elemene as maintain treatment for complete remission patients of newly diagnosed malignant gliomas following standard treatment, is able to delay tumor growth, or impact how long people with newly diagnosed high-grade glioma.

Detailed Summary: This study is being conducted to help determine whether β-elemene as maintain treatment for complete remission patients of newly diagnosed malignant gliomas following standard treatment, is able to delay tumor growth, or impact how long people with newly diagnosed high-grade glioma. β-elemene will be given 600mg/d,d1-14,q28 days for 6 cycles.
Sponsor: Sun Yat-sen University

Current Primary Outcome: Over-all survival [ Time Frame: 5-year ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Quality of life [ Time Frame: 5-year ]

Original Secondary Outcome: Same as current

Information By: Sun Yat-sen University

Dates:
Date Received: December 10, 2015
Date Started: April 2015
Date Completion: May 2018
Last Updated: December 11, 2015
Last Verified: December 2015